Cargando…
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()()
PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule inhibitor of MDM2 with improved pharmacokinetics over nutlin-3,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840291/ https://www.ncbi.nlm.nih.gov/pubmed/27108384 http://dx.doi.org/10.1016/j.neo.2016.01.006 |
_version_ | 1782428255947587584 |
---|---|
author | Feng, Felix Y. Zhang, Yu Kothari, Vishal Evans, Joseph R. Jackson, William C. Chen, Wei Johnson, Skyler B. Luczak, Connor Wang, Shaomeng Hamstra, Daniel A. |
author_facet | Feng, Felix Y. Zhang, Yu Kothari, Vishal Evans, Joseph R. Jackson, William C. Chen, Wei Johnson, Skyler B. Luczak, Connor Wang, Shaomeng Hamstra, Daniel A. |
author_sort | Feng, Felix Y. |
collection | PubMed |
description | PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule inhibitor of MDM2 with improved pharmacokinetics over nutlin-3, for sensitization of prostate cancer cells to radiotherapy and androgen deprivation therapy, a standard treatment option for men with high-risk prostate cancer. EXPERIMENTAL DESIGN: The effect of MDM2 inhibition by MI-219 was assessed in vitro and in vivo with mouse xenograft models across multiple prostate cancer cell lines containing varying p53 functional status. RESULTS: MDM2 inhibition by MI-219 resulted in dose- and time-dependent p53 activation and decreased clonogenic cell survival after radiation in a p53-dependent manner. Mechanistically, radiosensitization following inhibition of MDM2 was largely the result of p53-dependent increases in apoptosis and DNA damage as evidenced by Annexin V flow cytometry and γ-H2AX foci immunofluorescence. Similarly, treatment with MI-219 enhanced response to antiandrogen therapy via a p53-dependent increase in apoptotic cell death. Lastly, triple therapy with radiation, androgen deprivation therapy, and MI-219 decreased xenograft tumor growth compared with any single- or double-agent treatment. CONCLUSION: MDM2 inhibition with MI-219 results in p53-dependent sensitization of prostate cancer cells to radiation, antiandrogen therapy, and the combination. These findings support MDM2 small molecule inhibitor therapy as a therapy intensification strategy to improve clinical outcomes in high-risk localized prostate cancer. TRANSLATIONAL RELEVANCE: The combination of radiotherapy and androgen deprivation therapy is a standard treatment option for men with high-risk prostate cancer. Despite improvements in outcomes when androgen deprivation therapy is added to radiation, men with high-risk prostate cancer have significant risk for disease recurrence, progression, and even death within the first 10 years following treatment. We demonstrate that treatment with MI-219 (an inhibitor of MDM2) results in prostate cancer cell sensitization to radiation and androgen deprivation therapy in vitro and in vivo. Triple therapy with MI-219, radiation, and androgen deprivation therapy dramatically decreased tumor growth compared with any single- or double-agent therapy. These findings provide evidence that inhibition of MDM2 is a viable means by which to enhance the efficacy of both radiation and androgen deprivation therapy and thereby improve outcomes in the treatment of prostate cancer. As such, further investigation is warranted to translate these findings to the clinical setting. |
format | Online Article Text |
id | pubmed-4840291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48402912016-05-03 MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() Feng, Felix Y. Zhang, Yu Kothari, Vishal Evans, Joseph R. Jackson, William C. Chen, Wei Johnson, Skyler B. Luczak, Connor Wang, Shaomeng Hamstra, Daniel A. Neoplasia Original article PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule inhibitor of MDM2 with improved pharmacokinetics over nutlin-3, for sensitization of prostate cancer cells to radiotherapy and androgen deprivation therapy, a standard treatment option for men with high-risk prostate cancer. EXPERIMENTAL DESIGN: The effect of MDM2 inhibition by MI-219 was assessed in vitro and in vivo with mouse xenograft models across multiple prostate cancer cell lines containing varying p53 functional status. RESULTS: MDM2 inhibition by MI-219 resulted in dose- and time-dependent p53 activation and decreased clonogenic cell survival after radiation in a p53-dependent manner. Mechanistically, radiosensitization following inhibition of MDM2 was largely the result of p53-dependent increases in apoptosis and DNA damage as evidenced by Annexin V flow cytometry and γ-H2AX foci immunofluorescence. Similarly, treatment with MI-219 enhanced response to antiandrogen therapy via a p53-dependent increase in apoptotic cell death. Lastly, triple therapy with radiation, androgen deprivation therapy, and MI-219 decreased xenograft tumor growth compared with any single- or double-agent treatment. CONCLUSION: MDM2 inhibition with MI-219 results in p53-dependent sensitization of prostate cancer cells to radiation, antiandrogen therapy, and the combination. These findings support MDM2 small molecule inhibitor therapy as a therapy intensification strategy to improve clinical outcomes in high-risk localized prostate cancer. TRANSLATIONAL RELEVANCE: The combination of radiotherapy and androgen deprivation therapy is a standard treatment option for men with high-risk prostate cancer. Despite improvements in outcomes when androgen deprivation therapy is added to radiation, men with high-risk prostate cancer have significant risk for disease recurrence, progression, and even death within the first 10 years following treatment. We demonstrate that treatment with MI-219 (an inhibitor of MDM2) results in prostate cancer cell sensitization to radiation and androgen deprivation therapy in vitro and in vivo. Triple therapy with MI-219, radiation, and androgen deprivation therapy dramatically decreased tumor growth compared with any single- or double-agent therapy. These findings provide evidence that inhibition of MDM2 is a viable means by which to enhance the efficacy of both radiation and androgen deprivation therapy and thereby improve outcomes in the treatment of prostate cancer. As such, further investigation is warranted to translate these findings to the clinical setting. Neoplasia Press 2016-04-20 /pmc/articles/PMC4840291/ /pubmed/27108384 http://dx.doi.org/10.1016/j.neo.2016.01.006 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Feng, Felix Y. Zhang, Yu Kothari, Vishal Evans, Joseph R. Jackson, William C. Chen, Wei Johnson, Skyler B. Luczak, Connor Wang, Shaomeng Hamstra, Daniel A. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title | MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title_full | MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title_fullStr | MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title_full_unstemmed | MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title_short | MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()() |
title_sort | mdm2 inhibition sensitizes prostate cancer cells to androgen ablation and radiotherapy in a p53-dependent manner()() |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840291/ https://www.ncbi.nlm.nih.gov/pubmed/27108384 http://dx.doi.org/10.1016/j.neo.2016.01.006 |
work_keys_str_mv | AT fengfelixy mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT zhangyu mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT kotharivishal mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT evansjosephr mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT jacksonwilliamc mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT chenwei mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT johnsonskylerb mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT luczakconnor mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT wangshaomeng mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner AT hamstradaniela mdm2inhibitionsensitizesprostatecancercellstoandrogenablationandradiotherapyinap53dependentmanner |